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Monocyte chemoattractant protein-1 and macrophage infiltra- progression of other forms of chronic renal disease [2].
tion in hypertensive kidney injury. During the last decade, we [3–5] and others [6–9] have
Background. We investigated whether monocyte chemoat- emphasized the role of mononuclear leukocyte infiltrationtractant protein-1 (MCP-1) is expressed in hypertensive nephro-
in experimental hypertensive renal injury. Macrophagesclerosis, and tested the effect of angiotensin II type 1 receptor
(MF) infiltration was observed in angiotensin II (Ang II)-blockade on MCP-1 expression and macrophage (MF) infil-
tration. dependent models of hypertensive nephrosclerosis [3, 6,
Methods. Rats with two-kidney, one-clip (2K1C) hyperten- 7, 9]. The identification of molecular mechanisms of mono-
sion with and without treatment with the angiotensin II type 1 cyte/MF infiltration in hypertensive nephrosclerosis mightreceptor antagonist valsartan (3 mg/kg/day) were studied. In
lead to the development of novel therapies. Recently, wethese animals as well as in spontaneously hypertensive rats
[4] and others [8] reported evidence for a role of the(SHR), stroke-prone SHR (SHR-SP), hypertensive mRen-2
transgenic rats (TGR), and respective control strains, MCP-1 interstitial cell adhesion molecule-1 in mononuclear leu-
expression in the kidney was investigated by Northern and kocyte infiltration in experimental renovascular hyper-
Western blots and by immunohistochemistry. Glomerular and tension.interstitial MFs were counted.
Chemokines that attract MFs [10, 11] could also playResults. In the nonclipped kidney of 2K1C rats, MCP-1 ex-
a role in kidney damage associated with high blood pres-pression was elevated at 14 and 28 days when significant MF
infiltration was present. MCP-1 was localized to glomerular sure [9, 10]. Wolf et al reported that the chemokine
endothelial and epithelial cells, interstitial and tubular cells, RANTES is associated with MF infiltration in Ang II-
MFs, and vascular smooth muscle cells. A similar pattern of
induced hypertension [12]. In the present studies, weMCP-1 staining was present in TGR kidneys, whereas MCP-1
investigated the expression of monocyte chemoattrac-expression was not increased in SHR and SHR-SP. Valsartan
reduced but did not normalize blood pressure, blocked the tant protein-1 (MCP-1) [13, 14] in the kidney in rat mod-
induction of MCP-1 protein in 2K1C kidneys, and decreased els of hypertension. In vascular smooth muscle cells,
interstitial MF infiltration significantly. MCP-1 was shown to be induced by mechanical strain
Conclusion. MCP-1 expression is increased in angiotensin II-
[15] and by Ang II [16]. The chemokine MCP-1 is ex-dependent models of hypertensive nephrosclerosis and is tem-
pressed in experimental and human forms of immune-porally and spatially related to MF infiltration. The angiotensin II
type 1 receptor mediates the induction of MCP-1. mediated glomerulonephritis [17–22]. Several authors
provided direct evidence that blockade of MCP-1 reduces
monocyte/MF infiltration in antibody-induced experi-
Arterial hypertension is one of the leading causes of mental nephritis [18–21]. Our data show that MCP-1 ex-
end-stage renal failure; its incidence continues to rise de- pression is increased in some forms of experimental hy-
spite progress in antihypertensive treatment [1]. In addi- pertensive nephrosclerosis, mediated via the Ang II type 1
tion, arterial hypertension is an important factor in the (AT1) receptor, and is associated with monocyte/MF
infiltration.
Key words: nephrosclerosis, chemokines, end-stage renal failure, arte-
rial hypertension, angiotensin II type 1 receptor, inflammation.
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mals were allowed unlimited access to chow (#1320; Al- systolic blood pressure was determined before the ani-
mals were sacrificed.tromin, Lage, Germany) and tap water. All procedures
After weighing kidneys, the organs were decapsulated.performed on animals were done in accordance with
Part of each kidney was immediately snap frozen onguidelines of the American Physiological Society and
liquid nitrogen for protein and RNA extraction, whilewere approved by the local government authorities (Re-
a second part was put in methyl-Carnoy solution (60%gierung von Mittelfranken, AZ #621-2531.3-10/94).
methanol, 30% chloroform, and 10% glacial acetic acid)Two-kidney, one-clip renovascular hypertension (2K1C)
for fixation.was induced in male Sprague-Dawley rats (Charles River,
Sulzfeld, Germany) weighing 150 to 170 g by placing a
Northern blot detection of mRNAsilver clip of 0.2 mm internal diameter around the left renal
Total RNA was extracted using a modification of theartery through a flank incision under ether anesthesia, as
single-step method of Chomczynski with the TRI reagentpreviously described [3, 23]. Control animals underwent
(Molecular Research Center Inc., Cincinnati, OH, USA)the same procedure without placement of the clip. The
[29]. Tissue samples were stored at 2808C after snapanimals were then followed by weekly measurements of
freezing. Ice-cold (48C) TRI reagent was added immedi-weight and systolic blood pressure by tail-cuff plethys-
ately before processing the samples, and the samplesmography under light ether anesthesia [24]. Animals
were kept at 48C during the entire process of RNA ex-were only included in the 2K1C group if systolic blood
traction. For Northern blot analysis, 20 mg of total RNApressure was above 150 mm Hg, which was achieved in
were electrophoresed in a 1% agarose/1.8% formalde-80 to 90% of all operated animals. Animals that failed
hyde gel and transferred to positively charged Nylon mem-to thrive or lost weight were excluded [25]. Rats were
branes (Hybond N; Amersham, Braunschweig, Germany)sacrificed, and the kidneys were harvested at 4, 14, and
with 20 3 standard sodium citrate (SSC) overnight. Ethid-28 days after clipping (5 2K1C and 5 control animals at
ium bromide staining of the gel and membrane confirmedeach time point).
equal loading and sufficient blotting of the RNA. TheTo test for the role of the AT1, some animals were
RNA was fixed by baking for two hours at 808C.treated with the AT1 blocker valsartan. The animals re- The blots were probed with a full-length rat MCP-1ceived osmotic minipumps (Alzet model 2002; Alza Sci-
cDNA [14] and a 500 bp GAPDH probe [30]. DNAentific Products, Palo Alto, CA, USA) intraperitoneally,
fragments were radiolabeled with a[32]P-dCTP by randomwhich delivered 0.5 mL/hour for 14 days. Five 2K1C rats
prime labeling [31] with a commercially available kitreceived pumps with 55.8 mg/mL valsartan dissolved in
(Amersham). Prehybridization was performed at 428C0.5 mol/L KOH, pH 7.2; eight 2K1C rats and seven sham-
for two hours with a buffer containing 5 3 SSC, 0.1%
operated rats received minipumps filled with solvent (0.5
sodium dodecyl sulfate (SDS), 5 3 Denhardt’s solution,
mol/L KOH, pH 7.2). Fourteen days after implantation, 50 mmol/L Na2HPO4 (pH 6.5), 50% deionized for-all animals were instrumented with femoral artery cathe- mamide, and 250 mg/mL denatured salmon sperm DNA.
ters for intra-arterial blood pressure measurements under Hybridization was carried out under the same conditions
ether anesthesia as described previously [26]. Measure- for 24 hours. The membranes were washed twice with
ments were performed on the same day four hours after 2 3 SSC/0.1% SDS at 408C for 15 minutes and twice
termination of anesthesia via transducers (Grass Instru- with 0.2 3 SSC/0.1% SDS for 30 minutes at the same
ments, Quincy, MA, USA) connected to a polygraph temperature. Blots were then exposed to Kodak x-ray
(Hellige, Freiburg, Germany), and the animals were sac- films with intensifying screens.
rificed.
In addition, we studied three models of genetic hyper- Immunohistochemical detection of MCP-1
tension. Seven 12-week-old male rats heterozygous for After overnight fixation in methyl-Carnoy solution,
the mouse ren-2 transgene (TGR) with Ang II-dependent tissues were dehydrated by bathing in increasing concen-
hypertension [27], and six age-matched Sprague-Dawley- trations of methanol, followed by 100% iso-propanol.
Hannover (SDH) controls (Mo¨llegaard, Eijby, Denmark) From the paraffin-embedded tissues, 2 mm sections were
were sacrificed after measurement of systolic blood pres- cut with a Leitz SM 2000 R microtome (Leica Instruments,
sure. Four spontaneously hypertensive rats (SHRs) [28] Nussloch, Germany). After deparaffinization, endoge-
and four Wistar-Kyoto control animals (WKR; Charles nous peroxidase activity was blocked with 3% H2O2 in
River, Sulzfeld, Germany) were sacrificed at 12 weeks methanol for 20 minutes at room temperature.
of age after systolic blood pressure measurement. In addi- Sections were then layered with the primary MCP-1
tion, we also examined four stroke-prone SHR (SHR-SP) antibody and were incubated at 48C overnight. After addi-
and four respective WKY animals from the Heidelberg tion of the secondary antibody (dilution 1:500; biotin-
colony (Max-Delbru¨ck-Center, Berlin-Buch, Germany). conjugated, goat anti-rabbit immunoglobulin G; Dianova,
Hamburg, Germany), the sections were incubated withThese animals were also studied at 12 weeks of age;
Hilgers et al: MCP-1 in hypertensive nephrosclerosis2410
avidin horseradish peroxidase complex and exposed to protein was performed by incubating the membrane in
a 1:1000 dilution of a MCP-1 antibody and a peroxidase-0.1% diaminobenzidine tetrahydrochloride and 0.02%
H2O2 as a source of peroxidase substrate. The Vectastain conjugated secondary antibody. Peroxidase labeling was
detected with luminescence immunodetection (ECL;DAB kit (Vector Laboratory, Burlingame, CA, USA) was
used as a chromogen. Each slide was counterstained with Amersham).
hematoxylin. As negative controls, we used preimmune
Antibodiesrabbit IgG and staining with the secondary antibody (goat
anti-rabbit IgG) only. The antibody used to detect rat MCP-1 by immunohis-
tochemistry and immunofluorescence was kindly pro-
Double stainings for MCP-1 and specific cell markers vided by Dr. T. Yoshimura (National Cancer Institute/
Frederick Cancer Research and Development Center,Macrophages were counted after staining for the marker
ED-1 as described previously [3] and, in some experi- Frederick, MD, USA). The polyclonal rabbit anti-rat
MCP-1 antiserum [13, 14] was used at a dilution of 1:250.ments, after staining for the MF activity marker ED-3
[32]. For double stainings of MCP-1 and ED-1, sections For Western blot, a goat polyclonal anti-rat MCP-1 anti-
body (Santa Cruz Biotechnologies, Heidelberg, Germany)were stained for ED-1 first, followed by blocking the
peroxidase activity and subsequent staining for MCP-1. was used. The mouse monoclonal antibodies against cell
markers ED-1, ED-3, RECA, Thy-1, and WT-1 wereTo detect ED-1 staining, the Vector VIP substrate kit for
peroxidase (Vectastain) was used, resulting in a purple purchased from Serotec (Biozol, Eching, Germany) or
Santa Cruz Biotechnologies, respectively. The synapto-staining.
To localize MCP-1 in specific glomerular cells, the podin antibody was obtained from ProGen Biotechnics
GmbH (Heidelberg, Germany). These antibodies weresame methods were used for double stainings with MCP-1
antiserum and antibodies against markers for endothelial used at a dilution of 1:250, except for the WT-1 antibody,
cells (RECA-1) [33] and podocyte nuclei (WT-1) [34]. which was diluted 1:50.
In addition, double immunofluorescence was performed
Analysis of dataon cryostat sections of snap-frozen tissue as described
previously [3]. Immunofluorescence for MCP-1 was com- Intraglomerular ED-1–positive cells were counted in
bined with immunofluorescence for either the mesangial all glomeruli of a given kidney section (100 to 300 glo-
cell marker Thy-1 or synaptopodin, which stains podo- meruli, no selection) and were expressed as cells per
cyte foot processes and endothelial cells [34]. Primary glomerular section. Interstitial ED-1–positive cells were
antibodies were applied simultaneously over night at counted in 30 medium-power (magnification 325) corti-
48C. After washing, sections were incubated with second- cal views per section and were expressed as cells per
ary antibodies, CY2-labeled goat anti-mouse IgG, and square millimeter. Counting was begun in a random cor-
CY3-labeled goat anti-rabbit IgG (both from Dianova) tical field and in consecutive nonoverlapping cortical
at the same time for two hours. fields to the right of the previous view without selection;
if necessary, counting was continued at the opposite (left)
Western blot detection of MCP-1 protein edge of the section. In some experimental groups, cells
Rat kidney protein was extracted with TRI reagent positive for ED-3, a marker for activated MFs [32], were
by the method of Chomczynski [29]. The protein content counted in the same manner. Two-way analysis of vari-
was determined with a protein assay kit (Pierce, Rock- ance (ANOVA), followed by post hoc Newman-Keuls
ford, IL, USA), was made to 1 mg/mL with SDS sample test with adjustment for multiple comparisons, was used
buffer (50 mmol/L Tris-HCl, pH 6.8, 20% SDS, 2% mer- to test significance of differences between groups. A P
captoethanol, 0.01% Coomassie Brilliant Blue-G, 12% value , 0.05 was considered significant. The procedures
glycerol), and was boiled for five minutes. Equal amounts were carried out using the Statistica software (StatSoft,
of protein (35 mg/lane) were loaded onto a denaturing Tulsa, OK, USA). Values are displayed as means 6
10 to 18% SDS-polyacrylamide gradient gel in the buffer standard error of the mean (SEM).
system described by Schagger and von Jagow [35]. Sigma
Color Ultra Low Range molecular weight markers (1.06
RESULTSto 26.6 kD; Sigma Chemicals, Deisenhofen, Germany)
In 2K1C animals, systolic blood pressure as measuredwere used as standards. Proteins were electroblotted
by tail-cuff plethysmography was increased at 4 daysonto nitrocellulose (Hybond ECL; Amersham), and
(139 6 8 vs. 115 6 8 mm Hg in controls, P , 0.05), 14membranes were stained with Amido Black staining so-
days (153 6 7 vs. 112 6 4 mm Hg in controls, P , 0.05),lution (Sigma Chemicals) to test for complete protein
and 28 days after clipping (190 6 13 vs. 115 6 11 mm Hgtransfer. To prevent nonspecific antibody binding, mem-
in controls, P , 0.05). Similar elevations of systolic bloodbranes were blocked with 3% horse serum/bovine serum
albumin (BSA) overnight at 48C. Detection of MCP-1 pressure were found in TGR (189 6 8 vs. 106 6 4 mm Hg
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in SDH, P , 0.05) and SHR-SP (190 6 9 vs. 110 6
5 mm Hg in WKY). In SHR, systolic blood pressure was
increased to a somewhat lower extent (160 6 9 vs. 112 6
5 mm Hg in WKY, P , 0.05).
MCP-1 gene expression
Figure 1 shows the expression of MCP-1 mRNA in
individual kidneys of 2K1C, TGR, SHR, SHR-SP, and
WKY. Twenty-eight days after clipping, MCP-1 mRNA
was clearly increased (approximately fivefold) in the non-
clipped, right kidneys of 2K1C animals, whereas there
was no consistent increase of MCP-1 mRNA in clipped
kidneys (Fig. 1). Furthermore, MCP-1 mRNA was not
increased in the kidneys of SHR and SHR-SP, compared
with the respective control animals. In contrast, TGR
exhibited 2.8-fold increased mRNA levels for the chemo-
kine, compared with SDH control rats (Fig. 1).
Localization of MCP-1 protein
Monocyte chemoattractant protein-1 staining was de-
tected in glomeruli, vessels, tubular, and interstitial cells
of the contralateral kidneys of 2K1C animals (Fig. 2).
Some degree of staining of the smooth muscle cell layer
of interlobular arteries and afferent arterioles was pres-
ent in control animals (Fig. 2A) and clipped kidneys
as well. However, no glomerular, tubular or interstitial
MCP-1 staining was observed in clipped kidneys (data not
shown) or control animals (Fig. 2A). Within glomeruli,
MCP-1 staining was not detected in mesangial cells (Fig. 3).
However, MCP-1 staining was detected occasionally in
endothelial cells, more often in cells with WT-1–positive
nuclei, and partly colocalized with synaptopodin staining
(Fig. 3). These findings suggest that glomerular MCP-1
staining was localized to endothelial cells and, more
markedly, to podocytes.
The most conspicuous MCP-1 staining was observed in
peritubular interstitial cells (Fig. 2C). Staining of tubular
cells (Fig. 2D) was occasionally encountered but was
Fig. 1. Autoradiographs of Northern blots of 20 mg total kidney RNAquite rare (less than one stained tubule per kidney sec-
hybridized with a rat monocyte chemoattractant protein-1 (MCP-1) probe.tion) compared with peritubular MCP-1–positive areas
Each lane represents one individual kidney. The RNA gel stained by ethid-
similar to the one shown in Figure 2C (,10 to 30 areas ium bromide is shown below the autoradiographs. (A) Two kidney-one clip
(2K1C) hypertension 28 days after clipping: nonclipped, contralateral kid-per kidney section).
neys, clipped kidneys, and kidneys from sham-operated (sham) rats. (B)In TGR kidneys, the pattern of MCP-1 staining was RNA from ren-2 transgenic hypertensive rats (TGR) and Hannover Sprague-
Dawley controls (SDH). (C) Spontaneous hypertensive rats (SHR), strokeessentially the same as in the contralateral kidneys of
prone SHR (SHR-SP), and Wistar-Kyoto (WKY) rat kidney RNA.2K1C (data not shown). In SHR, no MCP-1 staining was
found, except the weak staining of small arteries and
arterioles, which was also present in all nonhypertensive
MCP-1 and monocyte/macrophage infiltrationcontrol animals, including WKY. In SHR-SP, there was
no cortical interstitial or glomerular MCP-1 staining. In the nonclipped, contralateral kidneys of 2K1C, the
However, local MCP-1 staining was present at the perim- development of hypertension was associated with mono-
eter of juxtamedullary necrotic lesions (Fig. 4), which cyte/MF infiltration in both glomeruli and the interstitial
were presumably caused by fibrinoid necrosis of juxta- space (Fig. 5). In contrast, clipped kidneys exhibited ele-
vated interstitial ED-1–positive cell counts only at themedullary glomeruli or vessels.
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Fig. 2. Double immunostaining for MCP-1 (orange brown) and the MF/monocyte marker ED-1 (dark purple cytoplasm). Hematoxylin counterstain
(blue nuclei). (A) Kidney section of a sham-operated rat (magnification 3400), representative for five rats. Staining of a preglomerular vessel for
MCP-1 is indicated by an asterisk. (B–E) From contralateral, nonclipped kidneys of 2K1C rats 28 days after clipping (N 5 5). Some examples of
ED-1–positive MFs are indicated by black arrows. Occasional MFs that also exhibited MCP-1 staining are indicated by white arrowheads. ED-1–positive
MFs were spatially associated with MCP-1 staining in glomeruli (B, magnification 3400), peritubular interstitium (C, magnification 3400), tubules
(D, magnification 3400), and injured vessels (E, magnification 3600).
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Fig. 3. Double stainings for MCP-1 and glomerular cell markers in contralateral kidneys of 2K1C rats 28 days after clipping (examples are
representative for 5 rats). (A) Double immunofluorescence for MCP-1 (red) and podocyte cytoplasmic marker synaptopodin (green), showing
partial colocalization (yellow, indicated by white arrow). Magnification 3400. (B) Double immunofluorescence for MCP-1 (red) and mesangial
cell marker Thy-1.1 (green), showing no colocalization. Magnification 3400. (C) Double immunohistochemistry for MCP-1 (purple) and rat
endothelial cell marker RECA (brown). Hematoxylin counterstain (blue nuclei), magnification 3800. Colocalization of MCP-1 and RECA is
indicated by a white arrow. (D) Double immunohistochemistry for MCP-1 (purple) and podocyte nuclear marker WT-1 (brown nuclei). Hematoxylin
counterstain (blue nuclei), magnification 3800. Some podocyte nuclei surrounded by MCP-1–positive cytoplasm are indicated by white arrows.
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Fig. 4. Juxtamedullary necrotic lesion in SHR-SP kidney, representative for four SHR-SP rats. (A ) MCP-1 immunostaining (black) at the perimeter
of the lesion (magnification 3250). (B) MF infiltration (ED-1 staining, black) surrounding the lesion (magnification 3250).
early days after clipping but not during the development of glomerular and interstitial monocyte/MF infiltration
in TGR kidneys (Fig. 6) was similar to the contralateralof hypertension (Fig. 5). Double stainings showed that
MCP-1 staining was spatially related to ED-1–positive kidney of 2K1C (Fig. 5). A smaller extent of glomerular
and interstitial monocyte/MF infiltration was seen inmonocytes/MFs (Fig. 2). Some ED-1–positive cells ap-
peared to stain for MCP-1 as well, but most MCP-1– SHR-SP (Fig. 6), whereas no significant infiltration was
noted in SHR compared with WKY (Fig. 6).positive cells did not stain for ED-1 (Fig. 2). The extent
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Fig. 6. Quantitation of macrophage infiltration in genetic models of
hypertension. TGR (N 5 7) were compared with SD rats (N 5 6), SHR
(N 5 4), and SHR-SP (N 5 4) with the respective WKY strains (N 5
4 rats for each strain). (A) Glomerular ED-1–positive cells, expressed
per glomerular cross-section. (B) Tubulointerstitial ED-1–positive cells
per square millimeter tubulointerstitial space. Data are mean 6 SEM.
Symbols are: (h) control (WKY/SD); (j) hypertensive rats. *P , 0.05
vs. normotensive controls.
that the induction of MCP-1 protein in cortical interstitial
and glomerular tissue of 2K1C right kidneys was almost
completely suppressed by valsartan (Fig. 9).
Glomerular infiltration of ED-1–positive total MFs
Fig. 5. Quantitation of macrophage infiltration in 2K1C kidneys. (A) and ED-3–positive activated MFs tended to be higher
Glomerular ED-1–positive cells, expressed per glomerular cross-sec-
in untreated 2K1C right kidneys (0.41 6 0.23 ED-1–tion. (B) Tubulointerstitial ED-1–positive cells per square millimeter
tubulointerstitial space. Data are mean 6 SEM of N 5 5 animals positive cells and 0.39 6 0.15 ED-3–positive cells per
each. Symbols are: (h) sham; ( ) clipped; (j) contralateral nonclipped glomerular cross-section) than in sham-operated rat kid-
kidneys. *P , 0.05 vs. sham-operated controls.
neys (0.26 6 0.12 ED-1–positive cells and 0.25 6 0.08
ED-3–positive cells), whereas valsartan-treated 2K1C
right kidneys displayed glomerular MF numbers similar
Effects of AT1 antagonism to sham-operated controls (0.30 6 0.11 ED-1–positive
During treatment of established 2K1C hypertension cells and 0.26 6 0.17 ED-3–positive cells per glomerular
with valsartan for two weeks, two 2K1C animals in the cross-section). However, there was no overall statistically
solvent group but none in the valsartan or sham-operated significant difference by ANOVA. In contrast, intersti-
groups died. Intra-arterial blood pressure measurements tial MF infiltration was significantly enhanced in 2K1C,
demonstrated that mean arterial pressure was signifi- which was abolished by valsartan (Fig. 7).
cantly lowered but not normalized by valsartan (Fig. 7).
The induction of MCP-1 mRNA in 2K1C right kidneys
DISCUSSIONexposed to high blood pressure was blunted by valsartan
Our results show that MCP-1 expression is increased(Fig. 8). Western blot analysis of renal cortical protein
in glomeruli and tubulointerstitial space in hypertensivefor MCP-1 detected several positive bands, in accordance
nephrosclerosis associated with Ang II-dependent hy-with previous results [13, 14, 36]. MCP-1 protein was
pertension (2K1C and TGR). The localization of MCP-1induced in 2K1C, which was completely abolished by
valsartan treatment. Immunohistochemistry confirmed protein was closely associated with MF infiltration into
Hilgers et al: MCP-1 in hypertensive nephrosclerosis2416
Fig. 8. (A) Autoradiograph of Northern blot of 20 mg total kidney
RNA hybridized with a rat MCP-1 probe. Each lane represents one
Fig. 7. Effects of valsartan treatment on mean arterial blood pressure individual right, nonclipped kidney. The RNA gel stained by ethidium
(A) and interstitial macrophage infiltration (B). Total MF numbers bromide is shown below the autoradiographs. (B) Western blot of
(ED-1–positive cells per mm2; j) and activated MFs (ED-3–positive kidney cortex protein (right, nonclipped kidneys) for MCP-1 protein.
cells per mm2; h) were counted. Data represent mean 6 SEM from In comparison to sham-operated controls, MCP-1 mRNA and protein
seven sham-operated, six untreated 2K1C, and five valsartan-treated are clearly induced in 2K1C rat kidneys. Valsartan (AT1RA) treatment2K1C rats. *P , 0.05 vs. sham operated control; §P , 0.05 vs. untreated normalizes MCP-1 mRNA and protein levels.
2K1C.
glomeruli and tubulointerstitial space of rat kidneys with in glomeruli of rats with supposedly nonimmunological
hypertensive kidney disease. Furthermore, our resultsnephrosclerosis. Blockade of the AT1 receptor abolished
the induction of MCP-1 and blunted MF infiltration in suggest that MCP-1 may play a role for MF infiltration
into the kidney in these experimental models. Thus, our2K1C rat kidneys. In contrast, little MCP-1 expression
or monocyte/MF infiltration was observed in SHR and data further support the hypothesis that inflammatory
mechanisms contribute to renal injury in Ang II-depen-SHR-SP. Our data show that the AT1 receptor induces
MCP-1 expression, which in turn may mediate monocyte/ dent forms of hypertension [3, 4, 6, 12].
Several lines of evidence suggest that Ang II mayMF infiltration in Ang II-dependent forms of hyperten-
sive nephrosclerosis. directly contribute to the induction of the chemokine
MCP-1 in hypertensive nephrosclerosis: Ang II has beenThe chemoattractant protein MCP-1, cloned by Yoshi-
mura et al in 1989 [13], has been identified as an important shown to increase MCP-1 synthesis in vascular smooth
muscle cells in vitro [16] and in vivo [15]. Blockade ofmediator of MF infiltration in several immune-mediated
inflammatory diseases of the kidney: Increased expres- Ang II in experimental models of immune-mediated glo-
merulonephritis reduced the induction of MCP-1 [37, 38].sion of MCP-1 was described in experimental and human
forms of glomerulonephritis [17, 22]. Moreover, inter- Activation of mitogen-activated kinases [16] and the
transcription factor nuclear factor-kB [37] may be in-vention studies with blocking antibodies demonstrated
that MCP-1 is an important chemoattractant for mono- volved in the signal transduction. The available evidence
suggests that the induction of MCP-1 by Ang II is medi-cytes/MFs in experimental anti-basement–membrane
crescentic glomerulonephritis [18–20] and experimental ated via the AT1 receptor [15, 16, 38]. Interestingly, the
AT2 receptor has been implicated in the induction of theanti–Thy-1.1 mesangioproliferative glomerulonephritis
[21]. Our data demonstrate that MCP-1 is clearly induced chemokine RANTES by Ang II [12]. Finally, mechanical
Hilgers et al: MCP-1 in hypertensive nephrosclerosis 2417
forces such as glomerular hypertension could directly
contribute to MCP-1 expression, which is increased by
shear stress in cultured endothelial cells in vitro [39].
Capers et al investigated MCP-1 expression in aortic tissue
of rats, using different models of hypertension, Ang II
infusion, and norepinephrine infusion, respectively, as
well as different forms of antihypertensive treatment
[15]. These authors elegantly demonstrated that both
hypertension and Ang II induce MCP-1 synthesis [15];
that is, MCP-1 expression was highest when both stimuli
were present. Our data do not allow us to decide whether
the reduced MCP-1 expression after valsartan treatment
was due to a direct effect of AT1 antagonism or to the
lowering of blood pressure. However, a direct AT1 effect
seems likely in view of the evidence discussed previously
in this article. In addition, the absence of MCP-1 expres-
sion in SHR animals argues against a major role of hyper-
tension per se for the induction of the chemokine.
We investigated which renal cells express MCP-1 in
hypertensive nephrosclerosis. MCP-1 staining was pres-
ent in interstitial cells and vascular smooth muscle cells.
Occasionally, ED-1–positive monocytes/MFs stained for
MCP-1, but by far most MCP-1–positive cells were nega-
tive for the monocyte/MF marker ED-1. In the glomeru-
lus, double stainings did not show MCP-1 in mesangial
cells, whereas there was a partial colocalization in podo-
cyte cytoplasm, and occasional staining of endothelial
cells. Others have described MCP-1 staining in mesangial
cells and/or Bowman’s capsule cells in experimental
forms of nephritis [10, 17, 22], but most authors did not
perform double stainings with specific cell markers. Part
of the MCP-1 staining we observed might be localized
to extracellular subepithelial or subendothelial deposits,
but immunogold electron microscopy will be required
to resolve this issue.
We observed a correlation between MCP-1 expression
and MF infiltration, both with respect to total (ED-1
positive) and activated (ED-3 positive) MFs. Because
MCP-1 localization was not restricted to MFs in the kid-
ney, these data suggest but do not prove that MCP-1 does
indeed contribute to MF infiltration into the kidney tissue.
Ang II could play a role in the activation of these MFs
[40, 41]. To determine the importance of MCP-1 for MF
influx and activation in hypertensive nephrosclerosis rel-
ative to other factors, blockade of the chemokine would
be required. In contrast to the immune-mediated models
Fig. 9. Representative examples of sections stained for MCP-1 (dark of glomerulonephritis, which were successfully treated
cytoplasm, arrowheads) from sham-operated (upper panel, N 5 7), with MCP-1 antibodies [18–21], the initial insult leading
untreated 2K1C (middle panel, N 5 6), and valsartan-treated 2K1C
to kidney injury is present for weeks or months in hyper-rats (lower panel, N 5 5). Hematoxylin counterstain (dark nuclei),
magnification 3400. All sections from right (contralateral) kidneys. tensive nephrosclerosis, rather than being restricted to
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